Harrow Health, Inc. (HROW) Stock

Harrow Health, Inc. specializes as a prominent player in the healthcare sector, focusing specifically on ophthalmology. The company operates ImprimisRx, a robust arm dedicated to ophthalmic outsourcing and pharmaceutical compounding. ImprimisRx plays a crucial role in delivering specialized medications tailored to meet the unique needs of patients and practitioners in the ophthalmology field. Additionally, Harrow Health, Inc. boasts DEXYCU in its portfolio, an innovative solution designed to treat post-operative inflammation effectively.

Beyond its core operations, Harrow Health, Inc. holds strategic equity interests in several prominent entities within the pharmaceutical landscape. These include Surface Ophthalmics, Inc., a clinical-stage company dedicated to advancing therapies for ocular surface diseases, and Melt Pharmaceuticals, Inc., which focuses on developing proprietary non-intravenous sedation and anesthesia therapeutics for various medical procedures. Moreover, the company has investments in Eton Pharmaceuticals, Inc., a commercial-stage entity actively engaged in the development and commercialization of pharmaceutical products.

Harrow Health, Inc. further enhances its portfolio through ownership of royalty rights in four clinical-stage drug candidates currently under development by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. These strategic investments underscore the company's commitment to advancing cutting-edge therapies that address critical medical needs in ophthalmology and beyond.

Founded in 2006 and headquartered in San Diego, California, Harrow Health, Inc. was initially known as Imprimis Pharmaceuticals, Inc. before rebranding in December 2018. The company continues to innovate and expand its presence in the healthcare industry, driven by a mission to improve patient outcomes through specialized pharmaceutical solutions.